Retatrutide is a triple agonist -it activates GLP-1 , GIP , and glucagon receptors
For BPC-157, cycling protocols serve two purposes: preventing potential receptor downregulation or tachyphylaxis, and avoiding any theoretical long-term risks associated with sustained peptide signaling
Triple-hormone-receptor agonist retatrutide for obesity, a phase 2 trial
That cleared the runway
Research published in Diabetes has shown that GLP-1 receptor activation in the central nervous system directly reduces food intake (Turton et al., 1996) Slowed gastric emptying GLP-1 delays how quickly food moves from the stomach into the small intestine, prolonging satiety after meals Enhanced insulin secretion GLP-1 stimulates glucose-dependent insulin release from pancreatic beta cells, helping regulate blood sugar without causing hypoglycemia Glucagon suppression Paradoxically, while retatrutide also activates the glucagon receptor directly, GLP-1 pathway activation suppresses inappropriate glucagon release after meals, helping stabilize postprandial blood sugar This is the same pathway that semaglutide targets, and it accounts for much of the appetite suppression that weight loss medications produce
In the phase 3 trial that measured outcomes at 20 weeks, most participants were able to reach the full dose and lost weight as their dose was increased
